Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Liabilities (2016 - 2025)

Cytosorbents (CTSO) has disclosed Total Liabilities for 14 consecutive years, with $36.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 5.97% year-over-year to $36.7 million, compared with a TTM value of $36.7 million through Sep 2025, up 5.97%, and an annual FY2024 reading of $36.3 million, up 20.94% over the prior year.
  • Total Liabilities was $36.7 million for Q3 2025 at Cytosorbents, up from $36.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $36.7 million in Q3 2025 and bottomed at $10.2 million in Q1 2021.
  • Average Total Liabilities over 5 years is $28.8 million, with a median of $27.9 million recorded in 2022.
  • The sharpest move saw Total Liabilities tumbled 55.4% in 2021, then skyrocketed 172.44% in 2022.
  • Year by year, Total Liabilities stood at $26.9 million in 2021, then grew by 3.4% to $27.9 million in 2022, then increased by 7.64% to $30.0 million in 2023, then grew by 20.94% to $36.3 million in 2024, then grew by 1.28% to $36.7 million in 2025.
  • Business Quant data shows Total Liabilities for CTSO at $36.7 million in Q3 2025, $36.4 million in Q2 2025, and $36.2 million in Q1 2025.